% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{BajwaTenBroeke:169971,
author = {S. W. Bajwa-Ten Broeke and A. Ballhausen$^*$ and A.
Ahadova$^*$ and M. Suerink and L. Bohaumilitzky$^*$ and F.
Seidler$^*$ and H. Morreau and T. van Wezel and J.
Krzykalla$^*$ and A. Benner$^*$ and N. F. de Miranda and M.
von Knebel Doeberitz$^*$ and M. Nielsen and M. Kloor$^*$},
title = {{T}he coding microsatellite mutation profile of
{PMS}2-deficient colorectal cancer.},
journal = {Experimental and molecular pathology},
volume = {122},
issn = {0014-4800},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2021-01671},
pages = {104668},
year = {2021},
note = {#LA:F210# / 2021 Oct;122:104668},
abstract = {Lynch syndrome (LS) is caused by a pathogenic heterozygous
germline variant in one of the DNA mismatch repair (MMR)
genes: MLH1, MSH2, MSH6 or PMS2. LS-associated colorectal
carcinomas (CRCs) are characterized by MMR deficiency and by
accumulation of multiple insertions/deletions at coding
microsatellites (cMS). MMR deficiency-induced variants at
defined cMS loci have a driver function and promote
tumorigenesis. Notably, PMS2 variant carriers face only a
slightly increased risk of developing CRC. Here, we
investigate whether this lower penetrance is also reflected
by differences in molecular features and cMS variant
patterns. Tumor DNA was extracted from formalin-fixed
paraffin-embedded (FFPE) tissue cores or sections (n = 90).
Tumors originated from genetically proven germline
pathogenic MMR variant carriers (including 14 PMS2-deficient
tumors). The mutational spectrum was analyzed using
fluorescently labeled primers specific for 18 cMS previously
described as mutational targets in MMR-deficient tumors.
Immune cell infiltration was analyzed by immunohistochemical
detection of T-cells on FFPE tissue sections. The cMS
spectrum of PMS2-deficient CRCs did not show any significant
differences from MLH1/MSH2-deficient CRCs. PMS2-deficient
tumors, however, displayed lower CD3-positive T-cell
infiltration compared to other MMR-deficient cancers (28.00
vs. 55.00 per 0.1 mm2, p = 0.0025). Our study demonstrates
that the spectrum of potentially immunogenic cMS variants in
CRCs from PMS2 gene variant carriers is similar to that
observed in CRCs from other MMR gene variant carriers. Lower
immune cell infiltration observed in PMS2-deficient CRCs
could be the result of alternative mechanisms of immune
evasion or immune cell exclusion, similar to those seen in
MMR-proficient tumors.},
keywords = {HNPCC (Other) / Hereditary colorectal cancer (Other) /
Immunology of cancer (Other) / Molecular pathways (Other)},
cin = {F210 / C060},
ddc = {610},
cid = {I:(DE-He78)F210-20160331 / I:(DE-He78)C060-20160331},
pnm = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
pid = {G:(DE-HGF)POF4-316},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34302852},
doi = {10.1016/j.yexmp.2021.104668},
url = {https://inrepo02.dkfz.de/record/169971},
}